Automated detection of neutralizing SARS-CoV-2 antibodies in minutes using a competitive chemiluminescence immunoassay
-
Published:2022-11-08
Issue:3
Volume:415
Page:391-404
-
ISSN:1618-2642
-
Container-title:Analytical and Bioanalytical Chemistry
-
language:en
-
Short-container-title:Anal Bioanal Chem
Author:
Klüpfel Julia,Paßreiter Sandra,Rumpf Melina,Christa Catharina,Holthoff Hans-Peter,Ungerer Martin,Lohse Martin,Knolle Percy,Protzer Ulrike,Elsner Martin,Seidel Michael
Abstract
AbstractThe SARS-CoV-2 pandemic has shown the importance of rapid and comprehensive diagnostic tools. While there are numerous rapid antigen tests available, rapid serological assays for the detection of neutralizing antibodies are and will be needed to determine not only the amount of antibodies formed after infection or vaccination but also their neutralizing potential, preventing the cell entry of SARS-CoV-2. Current active-virus neutralization assays require biosafety level 3 facilities, while virus-free surrogate assays are more versatile in applications, but still take typically several hours until results are available. To overcome these disadvantages, we developed a competitive chemiluminescence immunoassay that enables the detection of neutralizing SARS-CoV-2 antibodies within 7 min. The neutralizing antibodies bind to the viral receptor binding domain (RBD) and inhibit the binding to the human angiotensin-converting enzyme 2 (ACE2) receptor. This competitive binding inhibition test was characterized with a set of 80 samples, which could all be classified correctly. The assay results favorably compare to those obtained with a more time-intensive ELISA-based neutralization test and a commercial surrogate neutralization assay. Our test could further be used to detect individuals with a high total IgG antibody titer, but only a low neutralizing titer, as well as for monitoring neutralizing antibodies after vaccinations. This effective performance in SARS-CoV-2 seromonitoring delineates the potential for the test to be adapted to other diseases in the future.
Graphical Abstract
Funder
Technische Universität München
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry,Analytical Chemistry
Reference53 articles.
1. WHO. WHO Coronavirus Disease (COVID-19) dashboard. 2022. https://covid19.who.int/. Accessed 28 Sept 2022. 2. Schneider J, Mijočević H, Ulm K, Ulm B, Weidlich S, Würstle S, Rothe K, Treiber M, Iakoubov R, Mayr U, Lahmer T, Rasch S, Herner A, Burian E, Lohöfer F, Braren R, Makowski MR, Schmid RM, Protzer U, Spinner C, Geisler F. SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemic. Respir Res. 2021. https://doi.org/10.1186/s12931-021-01717-9. 3. Ayouba A, Thaurignac G, Morquin D, Tuaillon E, Raulino R, Nkuba A, Lacroix A, Vidal N, Foulongne V, Le Moing V, Reynes J, Delaporte E, Peeters M. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol. 2020. https://doi.org/10.1016/j.jcv.2020.104521. 4. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR, Chertow DS, Davey RT, Cohen JI. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020. https://doi.org/10.1093/infdis/jiaa273. 5. Faustini SE, Jossi SE, Perez-Toledo M, Shields AM, Allen JD, Watanabe Y, Newby ML, Cook A, Willcox CR, Salim M, Goodall M, Heaney JL, Marcial-Juarez E, Morley GL, Torlinska B, Wraith DC, Veenith TV, Harding S, Jolles S, Ponsford MJ, Plant T, Huissoon A, O’Shea MK, Willcox BE, Drayson MT, Crispin M, Cunningham AF, Richter AG. Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. Immunology. 2021. https://doi.org/10.1111/imm.13349.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|